InnovaRx Innova Health Strategies

N14.19

Nephropathy induced by other drugs, medicaments and biological substances

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 9 never code together
N10-N16block
Excludes1
  • pyeloureteritis cystica (N28.85)N28.85
N00-N99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 3
N14code
Code first
  • poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)T36-T65
Use additional code
  • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)T36-T50
N10-N16block
Includes
  • pyelonephritis
Index entries leading here 1
Alongside this code 1 same parent — N14.1
Medications 2

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

ESRD21HCC141

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
N14.1
Block
N10-N16
Siblings
1

Present FY2024–FY2027.